Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

Launched by GINEFIV · Oct 9, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating two different methods for stimulating the ovaries in women undergoing in vitro fertilization (IVF) with a focus on creating healthy embryos for genetic testing (called PGT-A). One method uses a new approach called Progestin-primed Ovarian Stimulation (PPOS), which helps avoid ovulation during the stimulation process and requires fewer injections. The other method is the conventional approach that uses medication to prevent premature ovulation. The goal is to see if both methods are equally effective in producing viable embryos.

To participate in this trial, women should have regular menstrual cycles and be planning to undergo IVF with PGT-A. They need to have both ovaries and be willing to complete the study. However, women with severe endometriosis or those already involved in another study cannot participate. If eligible, participants can expect to receive one of the two treatments and contribute to important research that may improve IVF procedures in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Regular menstrual cycles between 21 and 35 days, inclusive.
• • Indication of IVF with PGT-A.
• • Both ovaries present.
• • Ability to participate and complete the study.
• • Give and sign the consent to participate in the study.
• Exclusion Criteria:
• • Endometriosis grade III/IV
• • Concurrent participation in another study